The Significance of Bone Marrow Involvement in Aggressive Lymphomas: A Retrospective Comparison of Clinical Outcomes between Peripheral T Cell Lymphoma and Diffuse Large B Cell Lymphoma in China

Shuhua Yi a Gang An a Junyuan Qi a Dehui Zou a Yaozhong Zhao a Peihong Zhang a Huishu Chen a Jun Wang b Lugui Qiu a

a Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC), Tianjin, China; b Department of Pathology and Laboratory Medicine, Loma Linda University Medical Center, Loma Linda, Calif., USA

Key Words
Diffuse large B cell lymphoma · Immunophenotype · Peripheral T cell lymphomas · Prognosis

Abstract
Background: Peripheral T cell lymphomas (PTCL) have been demonstrated to have a poorer prognosis than diffuse large B cell lymphoma (DLBCL) due to a high frequency of bone marrow involvement (BMI). However, the clinical characteristics of PTCL with BMI have not been fully described, and the clinical outcomes of PTCL with BMI and DLBCL with BMI have not been well compared. Methods: The clinical characteristics and survival of 25 nodal PTCL cases with BMI and 42 DLBCL cases with BMI were compared. Results: Most of the PTCL patients with BMI had lymphadenopathy (88%), B symptoms (76%), an elevated LDH level (68%), anemia (64%), splenomegaly (60%), and a poor performance status (52%). Except for the differences of lymphadenopathy and thrombocytopenia between PTCL with BMI and DLBCL with BMI, similarities in gender, age, hepatomegaly, splenomegaly, a bulky mass, B symptoms, elevated LDH, ≥2 extranodal sites, ECOG scores ≥2, anemia, and international prognostic index (IPI) and age-adjusted IPI scores were observed between the 2 groups. The 2 groups also had similar 3-year overall survival (25.8 vs. 30.0%, p = 0.846) and progressive-free survival (21.3 vs. 25.2%, p = 0.815) rates. Conclusions: PTCL with BMI have a similar aggressive course and poor survival compared to DLBCL with BMI. Thus, the immunophenotype of either T or B lineage may not be a crucial prognostic indicator of survival for these 2 aggressive lymphomas.

Introduction
Peripheral T cell lymphomas (PTCLs) represent a heterogeneous group of disorders in the World Health Organization (WHO) classification [1], including angioimmunoblastic T cell lymphoma (AITL), PTCL unspecified (PTCL-u), and anaplastic large cell lymphoma (ALCL), which are mainly nodal PTCLs. Despite aggressive therapy, the prognosis of PTCLs is dismal, with 5-year overall survival (OS) ranges between 25 and 45% and more than...
It is unclear if these 2 diseases at a similar stage actually differ in terms of their clinical outcome.

Few studies have directly compared advanced stage DLBCL with PTCL, which is probably attributable to the rarity of PTCL as it accounts for only approximately 10% of all non-Hodgkin's lymphomas (NHL) encountered in the Western countries [5,11] and about 25% of those in Asia [12, 13]. Patients with PTCL with BMI were even fewer, i.e. only 6–30% of cases [10, 14–17]. In this study, we took advantage of the higher prevalence of PTCL with BMI and DLBCL with BMI in our hospital and retrospectively analyzed the clinical characteristics and outcomes of consecutive patients with PTCL with BMI compared with those of patients with DLBCL with BMI. Because the prognosis of ALK + ALCL is better than that of non-ALCL PTCL [17], ALCL cases were excluded from this study.

### Patients and Methods

**Patient Population**

The population enrolled into this study comprised 21 patients with PTCL-u, 4 patients with AITL (PTCL), and 42 patients with DLBCL, all of whom were diagnosed and treated at the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC). Histologic sections from each patient were reviewed by 2 hematopathologists (H.C. and J.Q.) and the diagnoses were confirmed according to the WHO classification [1]. All bone marrow tissues evaluated in this study were obtained at the time of the initial staging procedure. Clinical staging was performed before the initial therapy according to the Ann Arbor system. The international prognostic index (IPI) and the age-adjusted IPI (aaIPI) were routinely evaluated in all of the aggressive NHL patients at diagnosis.

The following clinical features were analyzed as potential prognostic factors: age(>60 vs. ≤ 60 years), gender, ECOG PS (scores 2–4 vs. 0–1), B symptoms (present or absent), LDH concentration (elevated vs. normal), hepatomegaly (present or absent), splenomegaly (present or absent), lymphadenopathy at diagnosis (present or absent), the number of ENS involved (≥2 vs. <2) (excluding BMI), the presence or absence of bulky disease (maximal diameter ≥10cm), hemoglobin concentration, platelet number (PLT), white blood cell (WBC), IPI, and aaIPI. Hemoglobin, PLT, and WBC were converted into appropriate binary variables.

**Treatment**

As shown in table 1, eleven patients (44.0%) in the PTCL group and 23 patients (54.8%) in the DLBCL group received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy. Nine patients (36.0%) in the PTCL group and 15 patients (35.7%) in the DLBCL group received a third-generation chemotherapy regimen [e.g. ProMACE-CytarBOM (methotrexate, prednisone, doxorubicin, cyclophosphamide, etoposide, cy-

### Table 1. Comparison of the primary clinical characteristics and therapeutic regimens between PTCL and DLBCL.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>DLBCL</th>
<th>PTCL</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt;60 years</td>
<td>6 (14.3)</td>
<td>3 (12.0)</td>
<td>1.000^a</td>
</tr>
<tr>
<td>Male gender</td>
<td>24 (57.1)</td>
<td>17 (68.0)</td>
<td>0.378^b</td>
</tr>
<tr>
<td>Lymphadenopathy present</td>
<td>26 (61.9)</td>
<td>22 (88.0)</td>
<td>0.022^b</td>
</tr>
<tr>
<td>Hepatomegaly present</td>
<td>14 (33.3)</td>
<td>8 (32.0)</td>
<td>0.911^b</td>
</tr>
<tr>
<td>Splenomegaly present</td>
<td>21 (50.0)</td>
<td>15 (60.0)</td>
<td>0.427^b</td>
</tr>
<tr>
<td>Bulky mass</td>
<td>2 (5.1)</td>
<td>3 (12.0)</td>
<td>0.371^a</td>
</tr>
<tr>
<td>ECOG PS ≥2</td>
<td>23 (54.8)</td>
<td>13 (52.0)</td>
<td>0.905^b</td>
</tr>
<tr>
<td>≥2 ENS involved</td>
<td>5 (11.9)</td>
<td>8 (32.0)</td>
<td>0.059^a</td>
</tr>
<tr>
<td>B symptoms present</td>
<td>30 (71.4)</td>
<td>19 (76.0)</td>
<td>0.683^b</td>
</tr>
<tr>
<td>Elevated LDH</td>
<td>27 (64.3)</td>
<td>17 (68.0)</td>
<td>0.757^b</td>
</tr>
<tr>
<td>Hemoglobin &lt;1g/dl</td>
<td>34 (81.0)</td>
<td>16 (64.0)</td>
<td>0.123^b</td>
</tr>
<tr>
<td>PLT &lt;100 × 10^9/l</td>
<td>24 (57.1)</td>
<td>7 (28.0)</td>
<td>0.021^b</td>
</tr>
<tr>
<td>WBC &gt;10 × 10^9/l</td>
<td>6 (14.3)</td>
<td>2 (8.0)</td>
<td>0.700^a</td>
</tr>
<tr>
<td>IPI score</td>
<td>0.143^b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–1</td>
<td>5 (11.9)</td>
<td>7 (28.0)</td>
<td>0.123^b</td>
</tr>
<tr>
<td>2</td>
<td>19 (45.2)</td>
<td>5 (20.0)</td>
<td>0.000^a</td>
</tr>
<tr>
<td>3</td>
<td>13 (31.0)</td>
<td>10 (40.0)</td>
<td>0.123^b</td>
</tr>
<tr>
<td>4–5</td>
<td>5 (11.9)</td>
<td>3 (12.0)</td>
<td>0.123^b</td>
</tr>
<tr>
<td>aaIPI score</td>
<td>0.087^b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.123^b</td>
</tr>
<tr>
<td>1</td>
<td>6 (16.7)</td>
<td>7 (30.4)</td>
<td>0.000^a</td>
</tr>
<tr>
<td>2</td>
<td>16 (44.4)</td>
<td>13 (56.5)</td>
<td>0.123^b</td>
</tr>
<tr>
<td>3</td>
<td>14 (38.9)</td>
<td>3 (13.1)</td>
<td>0.123^b</td>
</tr>
<tr>
<td>Therapeutic regimen</td>
<td></td>
<td></td>
<td>0.441^b</td>
</tr>
<tr>
<td>CHOP regimen</td>
<td>23 (54.8)</td>
<td>11 (44.0)</td>
<td>0.123^b</td>
</tr>
<tr>
<td>Intensive chemotherapy regimen</td>
<td>15 (35.7)</td>
<td>9 (36.0)</td>
<td>0.123^b</td>
</tr>
<tr>
<td>High-dose therapy plus ASCT</td>
<td>4 (9.5)</td>
<td>5 (20.0)</td>
<td>0.123^b</td>
</tr>
</tbody>
</table>

Figures in parentheses are percentages. PTCL indicates peripheral T-cell lymphoma unspecified plus angioimmunoblastic T-cell lymphoma. ASCT = Autologous stem cell transplantation. 
^a Fisher’s exact test.
^b χ² test.
tosine arabinoside, bleomycin, and vincristine) or MACOP-B (doxorubicin, cyclophosphamide, vincristine, methotrexate, bleomycin, and prednisone) or an even more intensive chemotherapy regimen such as HyperCVAD/MA (cyclophosphamide, doxorubicin, vincristine, prednisone, methotrexate, and cytarabine). These patients were defined as the intensive chemotherapy regimen group. The remaining 5 patients (20%) in the PTCL group and 4 patients (9.5%) in the DLBCL group were treated with high-dose chemotherapy plus autologous stem cell transplantation. No radiotherapy was added in the treatment course.

Assessment of Response

The response was evaluated based on the International Workshop Criteria reported in 1999 [18]. OS was measured as the interval between the date of the initial treatment and the date of death and/or the last follow-up. Progression-free survival (PFS) was measured as the interval between the date of the initial treatment and the date of death from any cause or disease progression.

Statistical Analysis

Fisher’s exact test or a χ² test was used to determine statistically significant differences between the clinical characteristics of the 2 groups. A survival curve was constructed using the Kaplan-Meier method, prognostic features were evaluated using univariate analysis (logrank test), and the effects of potential prognostic variables on survival were assessed according to the Cox regression method. p < 0.05 was considered statistically significant. All calculations were performed using the SPSS statistical software package (version 13.0).

Results

Clinical Characteristics

The patients’ ages ranged from 18 to 77 years (median 39 years) in the PTCL group and from 13 to 71 years (median 41 years) in the DLBCL group. The clinical characteristics of the patients are listed in table 1. BMI of PTCL was found predominantly in males, with a male-to-female ratio of 2.1:1. Most patients (88.0%) with PTCL with BMI had lymphadenopathy at diagnosis, while 76.0% had B symptoms, 68.0% had elevated LDH, 64.0% had anemia, 60.0% had splenomegaly, and 52.0% had scores >1 on the ECOG PS, indicating an aggressive clinical course. Compared with DLBCL, these 2 groups were similarly distributed with respect to gender, age, hepatomegaly, splenomegaly, a bulky mass, B symptoms, elevated LDH, ECOG PS ≥ 2, ≥ 2 ENS, hemoglobin <11 g/dl, and WBC >10 × 10⁹/l. The frequency of lymphadenopathy at diagnosis (88.0%) was higher in the PTCL group (p = 0.022), while the frequency of thrombocytopenia (57.1%) was higher in the DLBCL group (p = 0.021). Although there was a greater number of patients with unfavorable IPI scores in the PTCL group and a greater number of patients with unfavorable aaIPI scores in DLBCL group, no statistically significant differences were found between the 2 groups (p = 0.143 and p = 0.087, respectively).

Response and Survival

There were no statistically significant differences between the 2 groups with respect to therapy regimens (table 1). The response to the initial treatment was as follows: among the patients with PTCL, 16 patients achieved complete response or complete response uncertain (CR/CRu) (64%), 3 patients had a partial response (PR) (12%), and 6 patients (24%) had stable disease (SD) and progressive disease (PD). Among the patients with DLBCL, 21 patients achieved a CR/CRu (50%), while 9 patients had a PR (21.4%), and 12 patients had SD/PD (28.6%). The CR/CRu rates and the overall response rates (CR/CRu plus PR) between the 2 groups were similar (p = 0.316 and p = 0.780, respectively).

After a median follow-up of 11 months (42 months for surviving patients), 49 patients died. The median follow-up for survivors was 35.5 months in patients with PTCL and 45 months in patients with DLBCL. As expected, the survival of this population was poor in general. The median OS and PFS of the 67 patients was 13.0 ± 3.5 months (95% CI 6.2–19.8) and 11.0 ± 3.0 months (95% CI 5.2–16.8); the expected 3-year OS and PFS rates were 26.8 ± 5.7% and 23.9 ± 5.5%. The median OS was 13.0 ± 4.3 months (95% CI 4.5–21.5) in the DLBCL group and 14.7 ± 7.0 months (95% CI 1.0–28.3) in the PTCL group, respectively. The median PFS was 11.0 ± 3.7 months (95% CI 3.8–18.2) and 11.0 ± 4.7 months (95% CI 1.8–20.2) in each group, respectively. As is shown in figures 1 and 2, there were no statistically significant differences found between the 2 groups (p = 0.846 and p = 0.815, respectively).

Prognosis Analysis

Univariate analysis revealed that the presence of splenomegaly, elevated LDH, anemia and thrombocytopenia were significant predictors of a reduced OS (table 2), and these factors plus WBC >10 × 10⁹/l predicted an unfavorable PFS (table 3). Among these factors, only thrombocytopenia was observed more frequently in patients with DLBCL (table 1). Cox multivariate analysis was carried out based on factors that were positive in the univariate analysis. Only elevated LDH was an unfavorable predictor for OS and PFS, which was distributed equally in both groups. (table 2, 3).

Comparison of PTCL with BMI and DLBCL with BMI
PTCLs are a heterogeneous group of neoplasms accounting for 7–10% of NHL in the Western countries compared to 20–30% of NHL in East Asia, including China [5, 11–13]. Patients often present with an advanced stage of the disease, and the neoplasms are characterized by widespread dissemination and aggressive behavior. In T cell NHL, the frequency of BMI on initial diagnosis was 20–40% [8], and it was as high as 90.7% (42/54) in China [19]. However, the different frequencies of BMI may be associated with the different constituent ratios of subtypes at different research centers. Because of the rarity of their inci-
idence, the characteristics and outcomes of PTCL with BMI have not been well characterized. In this report, PTCL with BMI mostly occurred in young (median age 39 years) males (68%) and most of these patients had lymphadenopathy (88%), splenomegaly (60%), B symptoms (76%), elevated LDH levels (68%), anemia (64%), and poor PS (52%). Recently, Tang, et al. [20] from another Chinese institution reported a similar age range of disease onset (median age 42 years) and similar incidences of male-to-female ratio (64.2%), splenomegaly (67%), B symptoms (73%), elevated LDH levels (72%), and anemia (51%) in PTCL patients with BMI, but a lower incidence of lymphadenopathy (40%). The very poor survival of PTCL patients with BMI, with a median OS of 14.7 months, in the current study also correlates with the results of Tong et al. [20] (median OS 12 months). The common clinical characteristics from this study and the results of the study by Tang et al. [20] may reflect the unique features of PTCL with BMI in China.

Because of the rarity of PTCL and the relatively poor understanding of the clinical and biologic characteristics of these diseases, a comparison with a better-understood counterpart B cell lymphoma has always been carried out when studying PTCL. The obtained results, however, have been contradictory. Early studies by groups from Taiwan [12] and Stanford [21] revealed that there were considerable similarities between PTCL and DLBCL in terms of clinical stage, PS, ENS involvement, LDH level, and age distribution. Based on these studies, the survival of these lymphomas was also comparable [21], especially for the advanced-stage diseases [12, 21]. However, 2 more recent studies [7, 22] indicated that elevated LDH levels, poor PS, advanced stage, and B symptoms were observed more frequently in patients with PTCL than in patients with DLBCL, while a bulky mass was observed more frequently in patients with PTCL than patients with DLBCL. The survival of PTCL patients in both studies was also inferior to that of DLBCL patients. The difference between these studies might be explained by the different cases included and the sample size because the early studies included all subtypes of PTCL as 1 entity instead of individual subtypes of PTCL [12, 21]. Some ALK + ALCL patients might be included with a much improved survival in the PTCL group [17]. Some more recent investigations [7, 22] have directly compared non-ALCL nodal PTCL (AITL and/or PTCL–u) with DLBCL. Therefore, the conclusions from these recent studies [7, 22] might be more reliable.

As we know, both PTCL with BMI and DLBCL with BMI have poorer survival than those without BMI [8, 9], but the clinical characteristics and survival of these lymphomas have not been directly compared. Here, we performed the comparison between 25 PTCL patients with BMI and 42 DLBCL patients with BMI, excluding ALCL patients. Most of the clinical characteristics which were considered to have an impact on the prognosis of aggressive lymphoma, such as age, LDH level, ECOG scores, ENS involved, B symptoms, IPI, and aaIPI, were distributed equally between these 2 lymphomas. There was a significantly higher proportion (88.0%) of patients with lymphadenopathy at diagnosis in the PTCL group and a higher proportion (57.1%) of patients with a PLT <100 × 10^9/l in DLBCL group. The survival of both groups was similarly poor, with 3-year OS rates of 30.0 and 25.2% in the DLBCL and PTCL groups, respectively, but with no statistically significantly differences identified.

Immunophenotype has been generally regarded as a prognostic factor in patients with T cell or B cell lymphoid malignancies [5, 6, 11, 23, 24]. However, contradictory results have been obtained and few clinical trials have assessed whether the immunophenotype itself leads to poor outcomes and resistance to treatments. In recent literature, the T cell immunophenotype itself was not reported to have had an impact on the response to conventional chemotherapy, PFS, or OS [7, 22]. The poor prognosis in patients with PTCL was shown to be associated with initial clinical factors, such as poor scores on the IPI, rather than the immunophenotype itself [7, 22, 25]. In the current study, although lymphadenopathy at diagnosis and thrombocytopenia seem to be distributed in an unbalanced way between PTCL with BMI and DLBCL with BMI, neither factor appears to influence PFS and OS. Since the survivals between these 2 conditions are comparable, we assume that the immunophenotype of either T or B cell lineage does not have an impact on the prognosis of these 2 aggressive lymphomas.

In summary, although our study was retrospective in design and included a relatively small number of patients, DLBCL patients with BMI and PTCL patients with BMI showed comparable clinical characteristics, including IPI parameters. We have demonstrated that survival between the 2 groups was similar, implying that the immunophenotype alone may not be as critical a prognostic indicator of survival in aggressive lymphomas with BMI as currently believed.

**Acknowledgments**

This study was supported by grants from the Ministry of Public Health, People’s Republic of China (Clinic Key Project 2007–2009), and the Key Project of Tianjin Science and Technology Supporting Program (09ZCGYSF01000 and 09ZCZDSF038000).
References


